<DOC>
	<DOCNO>NCT01081041</DOCNO>
	<brief_summary>This study begin 30 participant lead-in part : 30 participant receive cetuximab manufacture ImClone weekly basis combination chemotherapy drug [ cisplatin carboplatin plus 5-fluorouracil ( 5-FU ) ] administer every 3 week . After 18 week , participant benefit treatment may continue receive cetuximab once-weekly progression disease , unacceptable side effect occur , participant withdraw consent , study close . In second part study , 200 participant randomize 2 arm : - 100 participant receive commercial cetuximab manufacture ImClone ( Group A ) - 100 participant receive cetuximab manufacture Boehringer Ingelheim ( Group B ) . All 200 participant receive chemotherapy drug ( cisplatin carboplatin plus 5-FU ) administer every 3 week . After 18 week , participant benefit treatment may continue receive cetuximab once-weekly progression disease , unacceptable side effect occur , participant withdraw consent , study close .</brief_summary>
	<brief_title>A Study Head Neck Cancer</brief_title>
	<detailed_description />
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Head neck cancer confirm tissue biopsy cytology Disease suitable local therapy Measurable evaluable disease Karnofsky performance status ( KPS ) score least 70 Organs function well ( bone marrow reserve , liver kidney ) Life expectancy least 12 week Signed informed consent document Receiving another investigational medication within last 30 day Prior chemotherapy , except give part multimodal treatment locally advanced head neck cancer complete 4 month prior study entry . Nasopharyngeal carcinoma Previous treatment monoclonal antibody therapy signal transduction inhibitor epidermal growth factor receptor ( EGFR ) target therapy except prior cetuximab treatment give part multimodal treatment locally advanced head neck cancer complete 4 month prior study entry . Uncontrolled high blood pressure Heart disease heart attack within last year Currently infection require take IV antibiotic Currently receive therapy cancer , chemotherapy , radiation therapy , immunotherapy , hormonal therapy Medical psychological condition would permit participant complete study sign inform consent Known drug abuse ( exception alcohol abuse ) Known allergic reaction component study treatment Second primary malignancy clinically detectable time consideration study enrollment Have another type cancer within last 2 year You currently pregnant breastfeed You consider become pregnant fathering child</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>